Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat. J Pediatr Gastroenterol Nutr 2001 Mar;32(3):270-3
Date
05/10/2001Pubmed ID
11345174DOI
10.1097/00005176-200103000-00007Scopus ID
2-s2.0-0035028691 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
BACKGROUND: The objective of the study was to determine whether ursodeoxycholic acid (Ursodiol) is protective against ibuprofen (IBU)-induced enteropathy.
METHODS: Using the chronically catheterized rat model, IBU (60 mg/kg body weight per day) was infused via the gastric catheter twice daily. Pancreatic enzyme (PE; 10,000 U lipase/kg body weight per day) and Ursodiol (10 mg/kg body weight per day) in two doses were infused via the duodenal catheter. Rats were assigned to one of six treatment groups and were administered treatment for 20 days: control, IBU, PE, IBU + PE, IBU + Ursodiol, and IBU + PE + Ursodiol. The entire jejunum, ileum, cecum, and colon were available for histologic analysis using previously described techniques.
RESULTS: Addition of Ursodiol to high-dose IBU and normal doses of PE showed a significant reduction in the percentage of rats with ulcers (P < 0.05), total number of serositis events (P < 0.01), total number of severe ulcers (P < 0.001), and an absence of ulcers in the large intestine.
CONCLUSIONS: Ursodiol, the drug of choice for the treatment of cystic fibrosis liver disease, may offer a safe method of using high-dose IBU in these patients by ameliorating the enteropathy.
Author List
Lloyd-Still JD, Beno DW, Uhing MR, Jiyamapa-Serna VA, Kimura REAuthor
Michael R. Uhing MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAnti-Inflammatory Agents, Non-Steroidal
Catheterization
Cholagogues and Choleretics
Cystic Fibrosis
Disease Models, Animal
Ibuprofen
Intestinal Diseases
Intestines
Lipase
Male
Random Allocation
Rats
Rats, Sprague-Dawley
Serositis
Ulcer
Ursodeoxycholic Acid
